Asset Details
Do you wish to reserve the book?
Type II cGMP-dependent protein kinase inhibits ligand-induced activation of EGFR in gastric cancer cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Type II cGMP-dependent protein kinase inhibits ligand-induced activation of EGFR in gastric cancer cells
Do you wish to request the book?
Type II cGMP-dependent protein kinase inhibits ligand-induced activation of EGFR in gastric cancer cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Type II cGMP-dependent protein kinase inhibits ligand-induced activation of EGFR in gastric cancer cells
2014
Overview
Our previous data demonstrated that type II cGMP-dependent protein kinase (PKG II) inhibited epidermal growth factor (EGF)-induced MAPK/ERK/JNK-mediated signal transduction through inhibiting the phosphorylation/activation of the epidermal growth factor receptor (EGFR). Since the EGFR also binds with several other ligands as well as EGF, the present study was designed to investigate whether PKG II inhibited transforming growth factor-α (TGF-α), betacellulin (BTC) and epiregulin (EPR) induced phosphorylation/activation of the EGFR and consequent MAPK/ERK-mediated signaling. The human gastric cancer cell line AGS, was infected with adenoviral constructs encoding cDNA of PKG II (Ad-PKG II) to increase the expression of PKG II and was treated with 8-pCPT-cGMP to activate the kinase. Western blotting was applied to detect the phosphorylation of EGFR and MAPK/ERK. The results demonstrated that treatment with EGF (100 ng/ml, 5 min), TGF-α (100 ng/ml, 5 min), BTC (100 ng/ml, 5 min) and EPR (100 ng/ml, 5 min) increased the tyrosine (tyr) 1068 phosphorylation of the EGFR and the threonine (thr) 202/tyr 204 phosphorylation of MAPK/ERK. Infecting the cells with Ad-PKG II and stimulating the kinase with 8-pCPT-cGMP efficiently inhibited the phosphorylation of the EGFR and MAPK/ERK induced by EGF, TGF-α, BTC and EPR. The results indicated that PKG II also inhibits the activation of the EGFR caused by diverse ligands of the receptor.
Publisher
D.A. Spandidos,Spandidos Publications,Spandidos Publications UK Ltd
Subject
/ Cyclic GMP-Dependent Protein Kinase Type II - metabolism
/ Enzyme Activation - drug effects
/ Epidermal Growth Factor - pharmacology
/ Epidermal growth factor receptors
/ Extracellular signal-regulated kinase
/ Extracellular Signal-Regulated MAP Kinases - metabolism
/ Humans
/ Intercellular Signaling Peptides and Proteins - pharmacology
/ Kinases
/ ligand
/ Ligands
/ Phosphorylation - drug effects
/ Phosphotyrosine - metabolism
/ Receptor, Epidermal Growth Factor - antagonists & inhibitors
/ Receptor, Epidermal Growth Factor - metabolism
/ Stomach Neoplasms - enzymology
/ Stomach Neoplasms - metabolism
/ Studies
/ Transforming Growth Factor alpha - pharmacology
/ type II cGMP-dependent protein kinase
/ Tyrosine
We currently cannot retrieve any items related to this title. Kindly check back at a later time.